JP2003516731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516731A5 JP2003516731A5 JP2001538519A JP2001538519A JP2003516731A5 JP 2003516731 A5 JP2003516731 A5 JP 2003516731A5 JP 2001538519 A JP2001538519 A JP 2001538519A JP 2001538519 A JP2001538519 A JP 2001538519A JP 2003516731 A5 JP2003516731 A5 JP 2003516731A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- polypeptide
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 description 61
- 239000000203 mixture Substances 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 27
- 108091033319 polynucleotide Proteins 0.000 description 26
- 102000040430 polynucleotide Human genes 0.000 description 26
- 239000002157 polynucleotide Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16654099P | 1999-11-18 | 1999-11-18 | |
| US60/166,540 | 1999-11-18 | ||
| US20363300P | 2000-05-11 | 2000-05-11 | |
| US60/203,633 | 2000-05-11 | ||
| PCT/US2000/031745 WO2001036640A2 (en) | 1999-11-18 | 2000-11-16 | Human fgf-21 gene and gene expression products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516731A JP2003516731A (ja) | 2003-05-20 |
| JP2003516731A5 true JP2003516731A5 (enExample) | 2007-11-22 |
Family
ID=26862338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538519A Pending JP2003516731A (ja) | 1999-11-18 | 2000-11-16 | ヒトｆｇｆ−２１遺伝子および遺伝子発現産物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1232264B1 (enExample) |
| JP (1) | JP2003516731A (enExample) |
| AT (1) | ATE446365T1 (enExample) |
| AU (1) | AU1922101A (enExample) |
| CA (1) | CA2392103A1 (enExample) |
| DE (1) | DE60043197D1 (enExample) |
| ES (1) | ES2335386T3 (enExample) |
| PT (1) | PT1232264E (enExample) |
| WO (1) | WO2001036640A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US20020032153A1 (en) * | 2000-03-10 | 2002-03-14 | Whitehouse Martha Jo | Methods and compositions for the treatment and prevention of erectile dysfunction |
| US20020151496A1 (en) * | 2000-12-08 | 2002-10-17 | Bringmann Peter W. | Novel fibroblast growth factors |
| JP2005519891A (ja) * | 2002-01-15 | 2005-07-07 | イーライ・リリー・アンド・カンパニー | 危篤状態の患者における罹病率および死亡率を低下させる方法 |
| CA2549249A1 (en) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| ATE444307T1 (de) * | 2004-09-02 | 2009-10-15 | Lilly Co Eli | Muteine des fibroblasten-wachstumsfaktors 21 |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| JP2006246823A (ja) * | 2005-03-11 | 2006-09-21 | Kyoto Univ | 造血因子としてのＦｇｆ２１の使用 |
| SI2068909T1 (sl) * | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modificirani fgf-21 polipeptidi in njihova uporaba |
| AU2012268895B2 (en) * | 2007-03-30 | 2015-07-16 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2358749B1 (en) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| BRPI1011404B1 (pt) * | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| EP2443145A1 (en) | 2009-06-17 | 2012-04-25 | Amgen, Inc | Chimeric fgf19 polypeptides and uses thereof |
| US8889625B2 (en) | 2009-07-10 | 2014-11-18 | Northwestern University | Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
| JP2013512672A (ja) | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質 |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| WO2012151349A1 (en) | 2011-05-03 | 2012-11-08 | Liu Shu Q | Neuroprotection by hepatic cells and hepatocyte secretory factors |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| TWI560202B (en) | 2011-12-22 | 2016-12-01 | Pfizer | Anti-diabetic compounds |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN103193878B (zh) * | 2013-04-03 | 2014-08-20 | 东北农业大学 | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| KR102728071B1 (ko) | 2015-08-03 | 2024-11-11 | 노파르티스 아게 | Fgf21-연관 장애를 치료하는 방법 |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| JP6991246B2 (ja) | 2017-02-08 | 2022-02-03 | ノバルティス アーゲー | Ｆｇｆ２１模倣抗体及びその使用 |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| TW202011029A (zh) * | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| US20220016211A1 (en) | 2020-01-08 | 2022-01-20 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586772T2 (de) | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | Verfahren zur bestimmung von mimotopen. |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| SE8903799D0 (sv) | 1989-11-13 | 1989-11-13 | Ericsson Telefon Ab L M | Foerfarande och anordning foer att variera slingbandbredden hos en faslaast slinga |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5252296A (en) | 1990-05-15 | 1993-10-12 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| JPH06500923A (ja) | 1990-09-21 | 1994-01-27 | カイロン コーポレイション | パッケージング細胞 |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| JP3337214B2 (ja) | 1990-12-20 | 2002-10-21 | アーチ・ディベロップメント・コーポレーション | 電離線による遺伝子発現の調節 |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| GB9406498D0 (en) | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| WO1997025345A1 (en) | 1996-01-05 | 1997-07-17 | Eli Lilly And Company | Fusion proteins comprising cell cycle regulatory proteins |
| NZ504425A (en) * | 1997-11-25 | 2001-10-26 | Genentech Inc | Nucleic acid molecules and polypeptides of fibroblast growth factor-19 (PRO533) |
| CA2367375A1 (en) * | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| DE60028054T2 (de) * | 1999-09-08 | 2006-12-21 | Genentech, Inc., South San Francisco | Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit |
| AU7368100A (en) * | 1999-09-10 | 2001-04-10 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
-
2000
- 2000-11-16 DE DE60043197T patent/DE60043197D1/de not_active Expired - Lifetime
- 2000-11-16 EP EP00982154A patent/EP1232264B1/en not_active Revoked
- 2000-11-16 PT PT00982154T patent/PT1232264E/pt unknown
- 2000-11-16 ES ES00982154T patent/ES2335386T3/es not_active Expired - Lifetime
- 2000-11-16 EP EP09173569A patent/EP2163626A1/en not_active Withdrawn
- 2000-11-16 JP JP2001538519A patent/JP2003516731A/ja active Pending
- 2000-11-16 AU AU19221/01A patent/AU1922101A/en not_active Abandoned
- 2000-11-16 WO PCT/US2000/031745 patent/WO2001036640A2/en not_active Ceased
- 2000-11-16 AT AT00982154T patent/ATE446365T1/de not_active IP Right Cessation
- 2000-11-16 CA CA002392103A patent/CA2392103A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516731A5 (enExample) | ||
| JP2003531583A5 (enExample) | ||
| RU2346951C2 (ru) | Выделенный полипептид, связывающий рецептор zalpha11-лиганда (варианты), кодирующий его полинуклеотид (варианты), вектор экспрессии (варианты) и клетка-хозяин (варианты) | |
| Takeya et al. | DNA sequence of the viral and cellular src gene of chickens. 1. Complete nucleotide sequence of an EcoRI fragment of recovered avian sarcoma virus which codes for gp37 and pp60src | |
| Rechavi et al. | Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element | |
| KR940010865B1 (ko) | 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법 | |
| KR20160067219A (ko) | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 | |
| Sundelin et al. | Amino acid sequence homologies between rabbit, rat, and human serum retinol-binding proteins. | |
| JP4189035B2 (ja) | 溶解性を向上させた組換えヒトインターフェロン−β | |
| JPH09322781A5 (enExample) | ||
| CA2143491A1 (en) | A novel peptide related to human programmed cell death and dna encoding it | |
| JP2006526414A5 (enExample) | ||
| JP2004537252A5 (enExample) | ||
| CA2641565A1 (en) | Nel-related proteins type 1 and 2, and polynucleotides encoding them | |
| CA2248667A1 (en) | Hla-a2.1 binding peptides and their uses | |
| CA2337100A1 (en) | Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same | |
| CA2179909A1 (en) | Ligand that binds fas antigen | |
| JP2003530124A5 (enExample) | ||
| JP2005523681A5 (enExample) | ||
| CA2135278A1 (en) | Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus | |
| JP2002517193A5 (enExample) | ||
| JP2008545393A5 (enExample) | ||
| JP2005519617A5 (enExample) | ||
| CA2301499A1 (en) | T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof | |
| JPWO2018234492A5 (enExample) |